Article Text

Download PDFPDF

36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study
  1. B You1,
  2. G Fleming2,
  3. M Bookman3,
  4. KN Moore4,
  5. KD Steffensen5 and
  6. RL Coleman6
  1. 1EMR UCBL/HCL 3738, Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Sud, GINECO, and Centre d’Investigation des Thérapeutiques en Oncologie et Hématologie de Lyon (CITOHL), Hospices Civils de Lyon (IC-HCL), France
  2. 2AbbVie, USA
  3. 3University of Chicago Medicine, USA
  4. 4Kaiser Permanente Northern California, USA
  5. 5Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, USA
  6. 6Lillebaelt University Hospital of Southern Denmark, and the University of Southern Denmark, Denmark


Introduction In VELIA (Phase 3), veliparib with carboplatin/paclitaxel (CP), followed by veliparib maintenance (veliparib-throughout) led to improved progression-free survival (PFS) vs CP alone (control). This exploratory analysis assessed the prognostic and predictive value of the modeled CA-125 elimination rate constant, KELIM.

Methods KELIM was estimated from treatment-related pharmacodynamic modeling of CA-125 values. Median KELIM was used to define favourable (≥median)/unfavourable (<median) KELIM groups. Patients were analyzed by surgery type: primary (PDS) or interval (IDS) debulking surgery.

Results In the IDS population (N=154), patients with favourable KELIM had a higher frequency of complete surgery vs unfavourable KELIM (51.9% vs 32.4%), confirming KELIM as a chemosensitivity marker. In both PDS (N=700) and IDS populations, median PFS was longer with favourable KELIM vs unfavourable KELIM, demonstrating a prognostic value. In the PDS population, median PFS was longer in the veliparib-throughout arm relative to control irrespective of KELIM (29.6 vs. 20.9 and 18.2 vs 15.4 months in favourable and unfavourable KELIM groups, respectively; figure 1). In the IDS population, median PFS was longer with veliparib-throughout vs control for patients with favourable KELIM only (29.3 vs 20.8 months; figure 2).

Abstract 36 Figure 1

Progression-free survival in the veliparib throughout arm and the control arm for KELIM subgroups in the PDS population

Abstract 36 Figure 2

Progression-free survival in the veliparib throughout arm and the control arm for KELIM subgroups in the IDS population

Conclusion In VELIA, KELIM was prognostic for PFS and IDS outcomes. Current data suggest KELIM may be associated with veliparib benefit. Ongoing analyses will explore how baseline characteristics contribute to KELIM predictive/prognostic value.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.